Recurrent EGFR-mutated non-small cell lung cancer discovered by abnormal mammogram: Adjuvant/frontline metastatic management options

1Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a discussion of evolving adjuvant and frontline metastatic management options in EGFR-mutated NSCLC, will be presented.

Cite

CITATION STYLE

APA

Copur, M. S., Lackner, R., Rodriguez, P., Horn, A. J., Faris, S., & Zusag, T. (2020). Recurrent EGFR-mutated non-small cell lung cancer discovered by abnormal mammogram: Adjuvant/frontline metastatic management options. ONCOLOGY (United States), 34(9), 347–351. https://doi.org/10.46883/ONC.2020.3409.0347

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free